Gaudium IVF and Women Health Q1 FY27 earnings call

Gaudium IVF and Women Health Limited reported a revenue of ₹19.4 crores for Q1 FY27, marking a 9.1% year-on-year growth. However, profitability saw a significant moderation, with reported EBITDA at ₹2.4 crores (down 52.96% YoY) and PAT at ₹1.8 crores (down 42.27% YoY). The reported EBITDA margin stood at 12.5%, a contraction of 1,651 basis points from 29% in Q1 FY26. Management attributed this to strategic investments and one-time^📎 expenses.

The moderation in Q1 FY27 profitability was a direct reflection of front-loaded expansion-related costs, including pre-operational spends for new centers and a heavy, one-time^📎 marketing push for the newly integrated AI-led embryology tools (SiD and ERICA). Excluding these one-off^📎 costs, the adjusted EBITDA would have been approximately ₹5.35 crores, with a margin of 27.63%, broadly in line with the company's steady-state operating profile. Management expects these investments to yield rewards throughout the rest of the year, leading to a recovery in adjusted margins similar to FY26 levels.

The company is progressing with its expansion plan, targeting 10 new hubs and corresponding spokes in FY27, followed by 8 in FY28 and 1 in FY29. The first new hub, the South Extension Centre, became operational on July 16, 2026. Two more hubs in Gurgaon and Nagpur are expected to be operational within 10 and 25 days, respectively. Additionally, Gaudium IVF is establishing three international spokes in Paris, Nigeria, and Sydney to tap into the growing medical tourism market, which currently contributes 25-30% of its patient mix.

Gaudium IVF has integrated AI-led embryology tools, SiD and ERICA, across its centers since April 1, 2026, positioning itself as the first IVF chain in India to do so. These tools enhance embryo and sperm selection consistency, leading to an approximately 8% improvement in first-attempt outcomes. This technology standardizes clinical precision, reduces reliance on individual human skill, and serves as a significant competitive differentiator, reinforcing Gaudium's clinical foundation.

Aligning with its long-term vision, Gaudium IVF is expanding beyond core IVF into broader women's health services, including gynaecology, obstetrics, and minimally invasive procedures. The board has approved an estimated project cost of up to ₹15 crores for a Gaudium Women Hospital in Lucknow, which will be funded through internal accruals and is expected to commercialize in FY28-FY29. This strategic move aims to offer comprehensive care and deepen patient wallet share.

The Indian fertility market is characterized by its large size and deep underpenetration, with nearly 27.5 million couples affected by infertility but only about 3 lakh IVF cycles performed annually. The company anticipates market consolidation as the ART and Surrogacy Act, introduced in 2022, progresses through its various phases of implementation. Gaudium IVF aims to capitalize on this by expanding its organized player share through ethical practices, consistent success rates, and awareness campaigns.

Gaudium IVF maintains a robust and debt-light balance sheet post its IPO, with cash and bank balances of ₹8.12 crores against borrowings of ₹26.74 crores, resulting in a consolidated debt-to-equity ratio of approximately 0.04 times. The company's FY27 capex plan of ₹25 crores for 10 new hubs will be funded through IPO proceeds and internal accruals. The Lucknow hospital project, with an estimated cost of up to ₹15 crores, will be funded entirely from internal accruals, demonstrating a commitment to financial discipline.